Skip to main content

Table 2 Characteristics of reviewed studies, ordered by base year of cost data

From: Economic analyses of breast cancer control in low- and middle-income countries: a systematic review

Authors Region / country Base year of cost data Study population Breast cancer stage considered Economic evaluation type Study design Perspective Time horizon Effectiveness outcome measure Sources for estimation of effectiveness Sources for estimation of resource utilization Discount rates used Sensitivity analysis for assumptions presented Incremental analysis reported
Groot and colleagues, 2006 [28] World sub-regions 2000 Female population at risk, in AfrE, AmroA, SearD All Cost-effectiveness analysis Model based Healthcare 100 years DALYs Literature based Secondary data collection On both costs and effects Yes Yes
Okonkwo and colleagues, 2008 [30] India 2001 Female population at risk All Cost-effectiveness analysis Model based Healthcare 25 years Life years saved Secondary data collection Secondary data collection On both costs and effects Yes Yes
Munshi, 2009 [41] Worldwide Varying from 2002 to 2007 Breast cancer patients in general All Report on costs and effects separately Other Healthcare NA Intermediate outcome measures Literature based Literature NA NA NA
Sarvazyan and colleagues, 2008 [32] Worldwide Varying from 2003 to 2007 Female population at risk All Cost-effectiveness analysis Other Not stated 1 year Life years saved Literature based Literature NA Yes No
Fonseca and colleagues, 2009 [38] Brazil 2005 Hypothetical cohort of 64-year-old postmenopausal women All Cost-effectiveness analysis Model based Healthcare Lifetime Life years saved Literature based Expert opinion On both costs and effects Yes Yes
Ginsberg and colleagues, 2012 [27] Sub-Saharan Africa and South East Asia 2005 Female population at risk, in SearD and AfrE All Cost-effectiveness analysis Model based Healthcare 100 years DALYs Literature based Secondary data collection On both costs and effects Yes Yes
Salomon and colleagues, 2012 [31] Mexico 2005 Female population at risk All Cost-effectiveness analysis Model based Healthcare 100 years DALYs Literature based Secondary data collection On both costs and effects Yes Yes
Pakseresht and colleagues, 2011 [48] India 2006/2007 103 women with primary breast cancer in a tertiary hospital All Cost analysis/cost of illness Observational Non-healthcare 2 years NA NA Primary data collection NA NA NA
Yazihan and Yilmaz, 2006 [34] Turkey 2007 Female population at risk All Cost-effectiveness analysis Other Healthcare 6 years DALYs Secondary data collection Secondary data collection None No No
Bastani and Kiadaliri, 2012 [49] Iran 2008 Patients younger than 75 with node-positive breast cancer All Cost-utility analysis Experimental Healthcare 8 months QALYs Primary data collection Primary data collection NA No NA
Liubao and colleagues, 2009 [39] China 2008 Model cohort of 1,000 51-year-old operable breast cancer patients All Cost-effectiveness analysis Model based Healthcare Lifetime QALYs Secondary data collection Secondary data collection On both costs and effects Yes Yes
Astim, 2011 [36] Turkey 2010 Female population at risk older than 30 All Report on costs and effects separately Model based Healthcare 10 years Intermediate outcome measures Secondary data collection Literature Yes No No
Zelle and colleagues, 2012 [35] Ghana 2010 Female population at risk All Cost-effectiveness analysis Model based Healthcare 100 years DALYs Literature based Primary data collection On both costs and effects Yes Yes
Bai and colleagues, 2012 [42] China 2012 Model cohort of women aged 51.7, with early stage breast cancer after lumpectomy 1 and 2 Cost-effectiveness analysis Model based Healthcare Lifetime QALYs Literature based Literature/expert opinion On both costs and effects Yes Yes
Arredondo and colleagues, 1995 [43] Brazil Not clear Hypothetical breast cancer case All Cost analysis/cost of illness Observational Healthcare NA NA NA Expert opinion NA No No
Boutayeb and colleagues, 2010 [37] Morocco Not clear Early-stage breast cancer patients in Morocco Not clear Cost-effectiveness analysis Observational Healthcare 1 year Life years saved Literature based Secondary data collection NA No No
Denewer and colleagues, 2010 [26] Egypt Not clear Female population at risk between 25 and 65 years All Report on costs and effects separately Experimental Healthcare 2 years Intermediate outcome measures Primary data collection Not clear None No No
Guggisberg and colleagues, 2011 [46] Cameroon Not clear Women who underwent FNA in a rural hospital All Report on costs and effects separately Observational Healthcare 5 weeks Intermediate outcome measures Primary data collection Not clear NA No No
Kobayashi, 1988 [44] Worldwide Not clear NA NA Cost analysis/cost of illness Observational Healthcare NA Intermediate outcome measures Primary data collection Primary data collection NA NA NA
Love and colleagues, 2002 [40] Vietnam and China Not clear Premenopausal Vietnamese and Chinese breast cancer patients, considered for surgery 2 Cost-effectiveness analysis Experimental Healthcare 15 years Life years saved Primary data collection Not clear On both costs and effects No Yes
Mousavi and colleagues, 2008 [29] Iran Not clear Female population at risk between 35 and 69 All Report on costs and effects separately Other Healthcare 1 year Life years saved Expert opinion Expert opinion NA No No
Nasrinossadat and colleagues, 2011 [47] Iran Not clear 51 patients that underwent surgical excision of nonpalpable breast masses All Report on costs and effects separately Observational Healthcare 3 to 4 years Intermediate outcome measures Primary data collection Not clear None No No
Thomas and colleagues, 1999 [45] Nigeria Not clear Patients who received FNA between 1994 and 1997 All Report on costs and effects separately Observational Patient NA Intermediate outcome measures Primary data collection Not clear NA NA NA
  1. DALYs, disability-adjusted life years; FNA, fine needle aspiration; NA, not applicable; QALYs, quality-adjusted life years.